Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use

High-resolution electrocardiography (HRECG) in detection of preclinical cardiotoxicity of sunitinib and sorafenib in renal cell carcinoma (RCC) patients

(2017) J. Mardiak et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

(2012) Edith A. Perez et al.   MAYO CLINIC PROCEEDINGS

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Sorafenib-associated multivessel coronary artery vasospasm

(2011) T. Naib et al.   HERZ

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations

(2011) J.D. Cohen et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient

(2011) Sang Ock Kim   WORLD JOURNAL OF GASTROENTEROLOGY

Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient

(2010) Yolanda B. Brauchli et al.   ACTA ONCOLOGICA

Safety Profile and Clinical Recommendations for the Use of Lapatinib

(2010) Dimitrios Chatsiproios   Breast Care

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

(2010) Guoqing Wei et al.   Journal of Hematology & Oncology

Recurrent myocardial infarction associated with gefitinib therapy

(2010) Donald R. Lynch et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

A case of variant angina in a patient under chronic treatment with sorafenib

(2010) Italo Porto et al.   Nature Reviews Clinical Oncology

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differences in Effects on Myocardium and Mitochondria by Angiogenic Inhibitors Suggest Separate Mechanisms of Cardiotoxicity

(2010) Kevin J. French et al.   TOXICOLOGIC PATHOLOGY

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

(2010) Brian B. Hasinoff et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

(2010) Brian B. Hasinoff   TOXICOLOGY AND APPLIED PHARMACOLOGY

Cardiotoxicity induced by tyrosine kinase inhibitors

(2009) George S. Orphanos et al.   ACTA ONCOLOGICA

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

(2009) H. Kantarjian et al.   BLOOD

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

(2009) Brian B. Hasinoff et al.   Cardiovascular Toxicology

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

(2009) C. L. Bello et al.   CLINICAL CANCER RESEARCH

Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase

(2009) Risto Kerkela et al.   CTS-Clinical and Translational Science

High rates of durable response are achieved with imatinib after treatment with interferon   plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

(2009) F. Guilhot et al.   HAEMATOLOGICA

Congestive heart failure during imatinib mesylate treatment

(2009) Gina Turrisi et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Magnetic Resonance Imaging in Sunitinib Malate-related Cardiomyopathy: No Late Gadolinium Enhancement

(2009) Ching-Fen Wu et al.   Journal of the Chinese Medical Association

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

(2009) F J Giles et al.   LEUKEMIA

Pazopanib

(2009) Ronald M. Bukowski et al.   NATURE REVIEWS DRUG DISCOVERY

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

(2008) M. L. Telli et al.   ANNALS OF ONCOLOGY

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib Induces Mitochondrial-Mediated Apoptosis in Human H3255 Non-Small-Cell Lung Cancer Cells with Epidermal Growth Factor ReceptorL858R Mutation through Mitochondrial Oxidative Phosphorylation-Dependent Activation of BAX and BAK

(2008) Y.-H. Ling et al.   MOLECULAR PHARMACOLOGY

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

(2008) Yvonne Will et al.   TOXICOLOGICAL SCIENCES